natgillin/translations-raw huggingface dataset:
micronized particles of glycopyrronium bromide, formoterol fumarate dihydrate, and, optionally, beclometasone dipropionate, as active ingredients, wherein said formulation is obtainable by a process comprising: 
mikronizirane čestice glikopironijeva bromida, formoterol-fumarat dihidrata, te, opcionalno, beklometazon-dipropionata, kao aktivnih tvari, gdje se rečena formulacija dobiva postupkom koji obuhvaća:
adding said glycopyrronium bromide to said first mixture, to obtain a second mixture, and mixing said second mixture at a speed of rotation not higher than 16 rpm for a time of 20 to 40 minutes, to obtain said formulation; and wherein the mid-fine particle fraction of glycopyrronium bromide is higher than 25%. 
dodavanje rečenog glikopironijeva bromida u rečenu prvu smjesu, da se dobije druga smjesa, te miješanje rečene druge smjese pri brzini rotacije ne većoj od 16 r.p.m. u vremenu ne dužem od 40 minuta; te gdje je srednja frakcija finih čestica glikopironijeva bromida viša od 25%.
further mixing said formulation obtained in (ii), to achieve a homogeneous distribution of said active ingredients. 
daljnje miješanje formulacije dobivene u (ii), da se postigne homogena distribucija rečenih aktivnih tvari.
a pharmaceutically acceptable carrier; and an additional therapeutic agent selected from a mucolytic agent, bronchodialator, an anti-biotic, an anti-infective agent, an anti-inflammatory agent, a cystic fibrosis transmembrane conductance regulator (CFTR) modulator, or a nutritional agent, wherein Form I is characterized as a crystal form having a monoclinic crystal system, a P21/n space group, and the following unit cell dimensions: 
farmaceutski prihvatljiv nosač; i dodatno terapeutsko sredstvo izabrano između mukolitičnog sredstva, bronhodilatora, antibiotika, anti-infektivnog sredstva, anti-upalnog sredstva, modulatora regulatora transmembranske provodljivosti u cističnoj fibrozi (CFTR), ili nutritivnog sredstva, gdje je oblik I karakteriziran kao kristalni oblik koji ima monoklinični kristalni sistem, prostornu grupu P21/n, i sljedeće dimenzije jedinične stanice:
The pharmaceutical composition according to claim 1, wherein the additional therapeutic agent is a CFTR modulator. 
Farmaceutski sastav prema zahtjevu 1, gdje je dodatno terapeutsko sredstvo CFTR modulator.
The pharmaceutical composition according to claim 1 or claim 2, wherein the CFTR modulator is N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide. 
Farmaceutski sastav prema zahtjevu 1 ili zahtjevu 2, gdje je CFTR modulator N-(5-hidroksi-2,4-diterc-butil-fenil)-4-okso-1H-kinolin-3-karboksamid.
A pharmaceutical composition according to any of claims 1 to 3 for use in a method of treating cystic fibrosis. 
Farmaceutski sastav prema bilo kojem od zahtjeva 1 do 3, za upotrebu u postupku liječenja cistične fibroze.
The pharmaceutical composition according to claim 1, wherein Form I is characterized as a crystal form having a monoclinic crystal system, a P21/n space group, and the following unit cell dimensions: 
Farmaceutski sastav prema zahtjevu 1, gdje je oblik I karakteriziran kao kristalni oblik koji ima monoklinični kristalni sistem, prostornu grupu P21/n, i sljedeće dimenzije jedinične stanice:
c = 33.075 (4) Å γ = 90°. The pharmaceutical composition according to claim 1, wherein Form I is characterized by one or more peaks at 15.4 degrees, 16.3 degrees, and 14.5 degrees in an X-ray powder diffraction obtained using Cu K alpha radiation at 40 kV, 35 mA. 
Farmaceutski sastav prema zahtjevu 1, gdje je oblik I karakteriziran sa jednim ili više vrhova na 15.4 stupnjeva ± 0.2 stupnja, 16.3 stupnjeva ± 0.2 stupnja, i 14.5 stupnjeva ± 0.2 stupnja u difrakciji redgneskih zraka na prahu dobivenih pomoću Cu K alfa zračenja na 40 kV, 35 mA.
Step b) Amination of a compound of formula (IV) to form said compound of formula (V) 
Korak b) Aminacija spoja formule (IV) u svrhu tvorbe navedenog spoja formule (V) [image]
A process according to claim 1, wherein step a) is performed with an azide reagent and a base in an organic solvent and followed by adding an alcohol at temperature range of 0 °C and 100 °C, particularly 80°C. 
Postupak prema patentnom zahtjevu 1, naznačen time, da se korak a) izvodi s azidnim reagensom i bazom u organskom otapalu, nakon čega slijedi dodavanje alkohola u temperaturnom rasponu od 0 °C do 100 °C.
A pharmaceutical composition, comprising a compound of any one of claims 1-12 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 
Farmaceutski sastav, koja sadrži spoj prema zahtjevu 1 ili njegovu farmaceutski prihvatljivu sol i farmaceutski prihvatljiv nosač.
A method for purifying an immunoglobulin from a sample comprising the immunoglobulin and at least one impurity on a large scale, the method comprising the following steps in the following order: 
Metoda pročišćavanja imunoglobulina iz uzorka koji sadrži imunoglobulin i barem jednu nečistoću, metoda obuhvaćajući sljedeće korake u sljedećem redoslijedu:
exposing the sample to anion exchange chromatography and obtaining the immunoglobulin, which is not bound to the anion exchange chromatography resin, in the flow-through; 
izlaganje uzorka kromatografiji anionske izmjene i dobivanje imunoglobulina, koji nije vezan na smolu kromatografije anionske izmjene, u protoku;
exposing the flow-through obtained in step (a) either to Protein A affinity chromatography, wherein the immunoglobulin is bound to the Protein A affinity chromatography resin, and obtaining the immunoglobulin in the eluate by eluting the protein from the Protein A affinity chromatography resin, or to Mixed Mode chromatography, wherein the immunoglobulin is bound to the Mixed Mode chromatography resin, and obtaining the immunoglobulin in the eluate by eluting the protein from the Mixed Mode chromatography resin; 
izlaganje protoka dobivenog u koraku (a) ili afinitetnoj kromatografiji proteina A, kod koje je imunoglobulin vezan na smolu afinitetne kromatografije proteina A, i dobivanje imunoglobulina u eluatu putem eluiranja proteina iz smole afinitetne kromatografije proteina A, ili kromatografiji mješovitog tipa, kod koje je imunoglobulin vezan na smolu kromatografije mješovitog tipa, i dobivanje imunoglobulina u eluatu putem eluiranja proteina iz smole kromatografije mješovitog tipa;
incubating the eluate obtained in step (b) at low pH of 2.5 to 4.5 for a defined time; 
inkubiranje eluata dobivenog u koraku (b) na niskoj pH vrijednosti od 2,5 do 4,5 na predodređeno vrijeme;
exposing the eluate after the incubation of step (c), or a composition derived therefrom and obtained after one or more further processing steps performed after step (c), to nanofiltration; 
izlaganje eluata nakon inkubacije iz koraka (c), ili sastava izvedenog iz istog i dobivenog nakon jednog ili više daljnjih procesnih koraka izvedenih nakon koraka (c), nanoflitraciji;
(c2) exposing the eluate obtained in step (c), or a composition derived therefrom and obtained after one or more further processing steps performed after step (c), to cation exchange chromatography, wherein the immunoglobulin is bound to the cation exchange chromatography resin, and obtaining the immunoglobulin in the eluate by eluting the protein from the cation exchange chromatography resin; 
(c2) izlaganje eluata dobivenog u koraku (c), ili sastava izvedenog iz istog i dobivenog nakon jednog ili više daljnjih procesnih koraka izvedenih nakon koraka (c), kromatografiji kationske izmjene, kod koje je imunoglobulin vezan na smolu kromatografije kationske izmjene, i dobivanje imunoglobulina u eluatu putem eluiranja proteina iz smole kromatografije kationske izmjene;
The method of claim 1, wherein the anion exchange chromatography of step (a) is strong anion chromatography comprising a ligand which is a strong anion exchange chromatography ligand except trimethylammoniumethyl bound to a methacrylate polymeric matrix, wherein the ligand is selected from the group consisting of quaternary aminoethyl (QAE) moieties, quaternary ammonium moieties and trimethylammonium moieties, wherein the ligand is preferably trimethylammonium (—N(CH3)3+). 
Metoda prema zahtjevima 1 do 5, pri čemu je kromatografija anionske razmjene iz koraka (a) jaka anionska kromatografija koja obuhvaća ligand koji je ligand jake anionske kromatografije osim trimetilamonijetila vezanog na polimersku metakrilatnu matricu, pri čemu je ligand odabran od skupine koja se sastoji od kvaternarnih aminoetil skupina, kvaternarnih amonijevih skupina i trimetilamonijevih skupina, pri čemu je ligand poželjno trimetilamonij (-N(CH3)3+).
Method for improving glycemic control in a patient with type 2 diabetes mellitus comprising administering to the patient a pharmaceutical composition according to claim 5 . The method according to claim 12, wherein said pharmaceutical composition is administered twice daily to the patient. Method for slowing the progression of, delaying or treating a metabolic disorder selected from the group consisting of type 2 diabetes mellitus, impaired glucose tolerance, impaired fasting blood glucose, hyperglycemia, postprandial hyperglycemia, overweight, obesity, metabolic syndrome, gestational diabetes, new onset diabetes after transplantation (NODAT) and complications associated therewith, and post-transplant metabolic syndrome (PTMS) and complications associated therewith in a patient in need thereof characterized in that an SGLT2 inhibitor, a DPP IV inhibitor and a third antidiabetic agent according to claim 1 are administered to the patient. 
SGLT2-inhibitor prema patentnom zahtjevu 1, koji se upotrebljava u postupku prevencije, usporavanja progresije, odgađanja ili liječenja metaboličkog poremećaja odabranog iz skupine koja se sastoji od sljedećih: dijabetes mellitus tipa 1, dijabetes mellitus tipa 2, oštećena tolerancija glukoze, pogoršanje razine glukoze u krvi na prazan želudac, hiperglikemija, hiperglikemija nakon uzimanja jela, prekomjerna težina, pretilost, metabolički sindrom, dijabetes u trudnoći, novi napad dijabetesa nakon transplantacije (NODAT) i komplikacije povezane s time, te post-transplantacijski metabolički sindrom (PTMS) i komplikacije povezane s time, za pacijenta kojemu je to potrebno, naznačen time, da se SGLT2-inhibitor, DPP-IV-inhibitor u skladu s patentnim zahtjevom 1 i treće antidijabetičko sredstvo u skladu s patentnim zahtjevom 1 ili 2, primjenjuju kod pacijenta u kombinaciji ili alternativno.
A nucleic acid, encoding a peptide according to any one of claims 1 to 4, or an expression vector capable of expressing said nucleic acid. 
Nukleinska kiselina koja kodira peptid u skladu s bilo kojim od patentnih zahtjeva 1, 3 ili 4, ili ekspresijski vektor koji može eksprimirati navedenu nukleinsku kiselinu.
A host cell comprising the nucleic acid or the expression vector according to claim 5, wherein said host cell preferably is an antigen presenting cell, for example a dendritic cell, and wherein said host cell is not a human embryonic stem cell. 
Stanica domaćin koja se sastoji od nukleinske kiseline ili ekspresijskog vektora u skladu s patentnim zahtjevom 5, pri čemu je navedena stanica domaćin poželjno antigen prezentirajuća stanica, na primjer, dendritična stanica, i pri čemu navedena stanica domaćin nije ljudska embrionska matična stanica.
An in vitro method for producing activated cytotoxic T lymphocytes (CTL), the method comprising contacting in vitro CTL with antigen loaded human class I MHC molecules expressed on the surface of a suitable antigen-presenting cell or an artificial construct mimicking an antigen-presenting cell for a period of time sufficient to activate said CTL in an antigen specific manner, wherein said antigen is a peptide according to claim 1. 
In vitro metoda za proizvodnju aktiviranih citotoksičnih T-limoficta (CTL) metoda je koja obuhvaća kontaktiranje in vitro CTL-a humanim MHC molekulama klase I ili II s umetnutim antigenima koje se eksprimiraju na površini odgovarajuće stanice koja prezentira antigen ili umjetnog spoja koji oponaša stanicu koja prezentira antigen u vremenskom razdoblju dovoljnom da se aktivira navedeni CTL na način svojstven antigenu, pri čemu je navedeni antigen peptid u skladu s bilo kojim od patentnih zahtjeva 1, 3 ili 4.
An antibody that is specific against the MHC/peptide complex of MHC with a peptide consisting of SEQ ID No. 6. 
Antitijelo koje je specifično protiv MHC/peptidnog kompleksa MHC-a s peptidom koji se sastoji od SEQ ID br. 1. Komplet koji sadrži:
adding any crystal form or amorphous form of the compound of formula (I) into an organic solvent to obtain a solution, heating the solution until it is clear, and then cooling the solution to precipitate a crystal, wherein the organic solvent is selected from the group consisting of esters, ketones, nitriles, and ethers, each of which having 5 or less carbon atoms, or a mixture thereof; and 
dodavanje bilo kojeg kristalnog oblika ili amorfnog oblika spoja iz formule (I) u odgovarajuću količinu organskog otapala, zagrijavanje otapala sve dok se ne razbistri, i zatim hlađenje da bi se istaložio kristal, pri čemu je organsko otapalo odabrano iz bilo kog od estera, ketona, nitrila, i etera koji imaju 5 ili manje atoma ugljika, ili njihovog mješovitog otapala;
The method according to claim 7, wherein a volume ratio of the two solvents in the mixed solvent is 1:10 to 10:1. 
Postupak sukladno patentnom zahtjevu 3, pri čemu je omjer obujma mješovitog otapala između 1:10 i 10:1, preporučljivo 1:1.
A recombinant CHO cell, comprising: 
Rekombinantna stanica CHO, naznačena time što sadrži:
The CHO cell of claim 3, wherein at least one copy of the genomic sequence of the C12orf35 gene, or at least 50% of coding sequence of said C12orf35 gene, is deleted. 
Stanica CHO u skladu s patentnim zahtjevom 2, naznačena time što je deletirana najmanje jedna kopija genomskog slijeda gena C12orf35, ili je deletirano najmanje 50% kodirajućeg slijeda navedenog gena C12orf35.
The CHO cell of claim 8, wherein said cell comprises a mutation in exon 2 of the matriptase gene. 
Stanica CHO u skladu s patentnim zahtjevom 7, naznačena time što navedena stanica sadrži mutaciju u eksonu 2 matriptaznog gena.
A large scale culture comprising the CHO cell of any one of claims 1-12, wherein said culture is at least 20 liter in size. 
Kultura u velikom mjerilu koja sadrži stanicu CHO u skladu s bilo kojim od patentnih zahtjeva 1-11, naznačena time što je navedena kultura velika najmanje 20 litara.
The large scale culture of 13, wherein the yield of CMV pentameric complex is at least 0.05 g/L. 
Kultura u velikom mjerilu u skladu s patentnim zahtjevom 12, naznačena time što je prinos pentamernog kompleksa iz CMV najmanje 0,05 g/l.
The ophthalmic aqueous solution according to claim 1 wherein the PGF2a analogue is tafluprost. 
Oftalmološka vodena otopina prema zahtjevu 1, gdje je spremnik jedinična doza ili jedinično dozni spremnik.
An antibody that is specific against the MHC/peptide complex of MHC with a peptide consisting of SEQ ID No. 
Antitijelo koje se veže specifično za peptid MHC/peptidni kompleks MHC-a s peptidom koji se sastoji od ID br.
A peptide according to any one of claims 1 to 4, the cell according to claim 7, or the activated cytotoxic T lymphocyte according to claim 11 for use in the treatment of cancer. 
Peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 4, stanica u skladu s patentnim zahtjevom 7 ili aktivirani citotoksični T-limfocit u skladu s patentnim zahtjevom 10 za upotrebu u liječenju karcinoma.
The peptide according to any one of claims 1 to 4, the cell according to claim 7, or the activated cytotoxic T lymphocyte according to claim 11 for use according to claim 12 in the form of a cancer vaccine. 
Peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 4, stanica u skladu s patentnim zahtjevom 7 ili aktivirani citotoksični T-limfocit u skladu s patentnim zahtjevom 10 za upotrebu u skladu s patentnim zahtjevom 11 u obliku cjepiva protiv karcinoma.
a container that contains a pharmaceutical composition containing a peptide according to any one of claims 1 to 4, the nucleic acid or the expression vector according to claim 5, a cell according to claim 7 or 8, or an activated cytotoxic T lymphocyte according to claim 11, in solution or in lyophilized form; and 
Komplet koji sadrži: posudu koja sadrži farmaceutski sastav koji sadrži peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 5, stanicu u skladu s patentnim zahtjevom 8 ili aktivirani citotoksični T limfocit u skladu s patentnim zahtjevom 11, u otopini ili u liofiliziranom obliku;
An isolated nucleic acid sequence coding for a hemicellulase, wherein the nucleic acid sequence is selected from the group consisting of: 
Izolirana sekvenca nukleinske kiseline koja kodira hemicelulazu, naznačena time što je sekvenca nukleinske kiseline odabrana iz skupine koja se sastoji od:
A nucleic acid construct or vector comprising the nucleic acid sequence according to claim 3. 
Konstrukt nukleinske kiseline ili vektor naznačen time što sadrži sekvencu nukleinske kiseline prema patentnom zahtjevu 3.
A recombinant cell comprising a polypeptide according to claim 1 or 2, a nucleic acid sequence according to claim 3 or a nucleic acid construct or vector according to claim 4, preferably the cell is a fungal cell, preferably a fungal cell selected from the group consisting of the genera Acremonium, Agaricus, Aspergillus, Aureobasidium, Chrysosporium, Coprinus, Cryptococcus, Filibasidium, Fusarium, Humicola, Magnaporthe, Mucor, Myceliophthora, Neocallimastix, Neurospora, Paecilomyces, Penicillium, Piromyces, Panerochaete, Pleurotus, Schizophyllum, Talaromyces, Rasamsonia, Thermoascus, Thielavia, Tolypocladium, and Trichoderma. 
Rekombinantna stanica koja sadrži polipeptid prema patentnom zahtjevu 1 ili 2, sekvencu nukleinske kiseline prema patentnom zahtjevu 3 ili konstrukt nukleinske kiseline ili vektor prema patentnom zahtjevu 4, poželjno je stanica gljivična stanica, poželjno je gljivična stanica odabrana iz skupine koja koja sadrži rodove Acremonium, Agaricus, Aspergillus, Aureobasidium, Chrysosporium, Coprinus, Cryptococcus, Filibasidium, Fusarium, Humicola, Magnaporthe, Mucor, Myceliophthora, Neocallimastix, Neurospora, Paecilomyces, Penicillium, Piromyces, Panerochaete, Pleurotus, Schizophillum, Talaromyces, Rasamsonia, Thermoascus, Thielavia, Tolypocladium, i Trichoderma.
A method according to claim 11, wherein before enzymatic treatment the substrate is pretreated with heat, mechanical and/or chemical modification or any combination of such methods. 
Postupak u skladu s patentnim zahtjevom 11, naznačen time što je prije enzimske obrade supstrat prethodno obrađen toplinskom, mehaničkom i/ili kemijskom modifikacijom ili bilo kojom kombinacijom takvih postupaka.
An antibody that is specific against the MHC/peptide complex of MHC with a peptide consisting of SEQ ID No. 
Antitijelo koje je specifično protiv MHC/peptidnog kompleksa MHC s peptidom koji se sastoji od SEQ ID br.
The co-crystal for use according to claim 1, wherein the radiation therapy is an adjuvant radiation therapy. 
Sukristal namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je terapija zračenjem adjuvantna terapija zračenjem.
The co-crystal for use according to claim 2, wherein the cancer is selected from breast cancer, colorectal cancer, gastric-esophageal cancer, fibrosarcoma, glioblastoma, hepatocellular carcinoma, head and neck squamous cell carcinoma, melanoma, lung cancer, pancreatic cancer or prostate cancer. 
Sukristal namijenjen upotrebi u skladu s patentnim zahtjevom 2, naznačen time što se rak bira između raka dojke, kolorektalnog raka, gastroezofagealnog raka, fibrosarkoma, glioblastoma, hepatocelularnog karcinoma, karcinoma pločastih stanica glave i vrata, melanoma, raka pluća, raka gušterače ili raka prostate.
The co-crystal for use according to claims 1 to 3, wherein a molar ratio of the adipic acid to the compound of formula I is about 1 to 2. 
Sukristal namijenjen upotrebi u skladu s patentnih zahtjeva 1 do 3, naznačen time što je molarni omjer između adipiske kiseline i spoja formule I otprilike 1 do 2.
the compound has a DSC peak in its DSC thermogram at about 195 °C and about 245 °C. 
spoj ima maksimum DSC u svom DSC termogramu kod otprilike 195 °C i otprilike 245 °C.
the compound has a DSC peak in its DSC thermogram at about 195 °C and about 245 °C; or 
spoj ima maksimum DSC u svom DSC termogramu kod otprilike 195 °C i otprilike 245 °C; ili
The co-crystal for use according to claim 8, wherein a molar ratio of the adipic acid to the compound of formula I is about 1 to 2 
Sukristal namijenjen upotrebi u skladu s patentnim zahtjevom 8, naznačen time što je molarni omjer između adipiske kiseline i spoja formule I otprilike 1 do 2.
the co-crystal is administered with an additional therapeutic agent, wherein the additional therapeutic agent comprises radiation therapy or chemotherapy, or both radiation therapy and chemotherapy; or 
sukristal se primijenjuje uz dodatno terapijsko sredstvo, gdje dodatno terapijsko sredstvo uključuje terapija zračenjem ili kemoterapiju, ili i terapiju zračenjem i kemoterapiju; ili
The oral pharmaceutical composition according to claim 6, wherein the content of the sugar alcohol or disaccharide is 3.6 parts by mass or more based on 1 part by mass of a,a,a-trifluorothymidine. 
Neobložena tableta prema patentnom zahtjevu 4, gdje je sadržaj šećernog alkohola ili disaharida 3.6 dijelova po masi ili više bazirano na 1 dijelu po masi a,a,a-trifluorotimidina.
a full-length antibody; and/or 
protutijelo pune duljine; i/ili
The bispecific antibody for use of any one of claims 27-29, wherein the bispecific antibody binds to (a) a CD3 molecule located on an immune effector cell and (b) a HER2 molecule located on a target cell other than the immune effector cell. 
Bispecifično protutijelo za uporabu prema bilo kojem od patentnih zahtjeva 19-21, naznačeno time, da se bispecifično protutijelo veže na (a) molekulu CD3 koja se nalazi na imunoefektorskoj stanici i (b) molekulu CD20 koja se nalazi na ciljnoj stanici koja je različita od imunoefektorske stanice.
The bispecific antibody for use of claim 30, wherein the bispecific antibody activates the immune effector cell following binding to (a) and (b). 
Bispecifično protutijelo za uporabu prema patentnom zahtjevu 22, naznačeno time, da bispecifično protutijelo aktivira imunoefektorsku stanicu što slijedi nakon vezanja na (a) i (b).
The bispecific antibody for use of claim 32, part (ii), wherein the PD-1 axis binding antagonist is selected from the group consisting of a PD-1 binding antagonist, a PD-L1 binding antagonist, and a PD-L2 binding antagonist. 
Bispecifično protutijelo za uporabu prema patentnom zahtjevu 24, dio (ii), naznačeno time, da se antagonist vezanja PD-1-osi odabire iz skupine koju čine: antagonist vezanja PD-1, antagonist vezanja PD-L1, i antagonist vezanja PD-L2.
a PD-1 binding antagonist selected from the group consisting of MDX-1106 (nivolumab), MK-3475 (lambrolizumab), CT-011 (pidilizumab), and AMP-224; 
antagonist vezanja PD-1 odabran iz skupine koja se sastoji od sljedećih: MDX-1106 (nivolumab), MK-3475 (lambrolizumab) i AMP-224;
a PD-L1 binding antagonist selected from the group consisting of: MPDL3280A, YW243.55. 
antagonist vezanja PD-L1 odabran iz skupine koja se sastoji od sljedećih: YW243.55.
a PD-L2 binding antagonist, wherein the PD-L2 binding antagonist is an antibody or an immunoadhesin. 
antagonist vezanja PD-L2, gdje antagonist vezanja PD-L2 je protutijelo ili imunoadhezin.
The bispecific antibody for use of any one of claims 27-35, wherein the bispecific antibody is formulated for administration to a subject subcutaneously, intravenously, intramuscularly, topically, orally, transdermally, intraperitoneally, intraorbitally, by implantation, by inhalation, intrathecally, intraventricularly, or intranasally. 
Bispecifično protutijelo za uporabu prema bilo kojem od patentnih zahtjeva 19-30, naznačeno time, da je bispecifično protutijelo formulirano za primjenu kod pojedinca davanjem supkutano, intravenozno, intramuskularno, topikalno, oralno, transdermalno, intraperitonealno, intraorbitalno, putem implantacije, putem inhalacije, intratekalno, intraventrikularno ili intranazalno.